دورية أكاديمية
أعرض في EDS

Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer.

التفاصيل البيبلوغرافية
العنوان: Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer.
المؤلفون: Wang Y; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.; State Key Laboratory of Oncology in Southern China, Guangzhou, 510060, China.; Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China., Tang Y; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.; State Key Laboratory of Oncology in Southern China, Guangzhou, 510060, China.; Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China., Liu Z; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.; State Key Laboratory of Oncology in Southern China, Guangzhou, 510060, China.; Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China., Tan X; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.; State Key Laboratory of Oncology in Southern China, Guangzhou, 510060, China.; Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China., Zou Y; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.; State Key Laboratory of Oncology in Southern China, Guangzhou, 510060, China.; Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China., Luo S; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.; State Key Laboratory of Oncology in Southern China, Guangzhou, 510060, China.; Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China., Yao K; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China. yaokai@sysucc.org.cn.; State Key Laboratory of Oncology in Southern China, Guangzhou, 510060, China. yaokai@sysucc.org.cn.; Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, China. yaokai@sysucc.org.cn.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China. yaokai@sysucc.org.cn.
المصدر: Scientific reports [Sci Rep] 2024 Jan 12; Vol. 14 (1), pp. 1216. Date of Electronic Publication: 2024 Jan 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Urinary Bladder Neoplasms*/genetics , Urinary Bladder Neoplasms*/therapy , Carcinoma, Transitional Cell*, Humans ; Retinoic Acid 4-Hydroxylase ; Inflammation/genetics ; Prognosis ; Immunotherapy ; Tumor Microenvironment/genetics
مستخلص: Tumor inflammation is one of the hallmarks of tumors and is closely related to tumor occurrence and development, providing individualized prognostic prediction. However, few studies have evaluated the relationship between inflammation and the prognosis of bladder urothelial carcinoma (BLCA) patients. Therefore, we constructed a novel inflammation-related prognostic model that included six inflammation-related genes (IRGs) that can precisely predict the survival outcomes of BLCA patients. RNA-seq expression and corresponding clinical data from BLCA patients were downloaded from The Cancer Genome Atlas database. Enrichment analysis was subsequently performed to determine the enrichment of GO terms and KEGG pathways. K‒M analysis was used to compare overall survival (OS). Cox regression and LASSO regression were used to identify prognostic factors and construct the model. Finally, this prognostic model was used to evaluate cell infiltration in the BLCA tumor microenvironment and analyze the effect of immunotherapy in high- and low-risk patients. We established an IRG signature-based prognostic model with 6 IRGs (TNFRSF12A, NR1H3, ITIH4, IL1R1, ELN and CYP26B1), among which TNFRSF12A, IL1R1, ELN and CYP26B1 were unfavorable prognostic factors and NR1H3 and ITIH4 were protective indicators. High-risk score patients in the prognostic model had significantly poorer OS. Additionally, high-risk score patients were associated with an inhibitory immune tumor microenvironment and poor immunotherapy response. We also found a correlation between IRS-related genes and bladder cancer chemotherapy drugs in the drug sensitivity data. The IRG signature-based prognostic model we constructed can predict the prognosis of BLCA patients, providing additional information for individualized prognostic judgment and treatment selection.
(© 2024. The Author(s).)
References: J Clin Invest. 2019 Jun 17;129(7):2964-2979. (PMID: 31205032)
Brief Bioinform. 2021 May 20;22(3):. (PMID: 32789507)
Medicina (Kaunas). 2021 Jul 24;57(8):. (PMID: 34440955)
Urol Oncol. 2020 Sep;38(9):706-712. (PMID: 32482511)
Mol Ther Oncolytics. 2021 Feb 04;20:410-421. (PMID: 33665361)
Chin Med J (Engl). 2022 Feb 9;135(5):584-590. (PMID: 35143424)
Eur Urol. 2021 Feb;79(2):214-221. (PMID: 32868138)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
Arch Biochem Biophys. 2003 Sep 1;417(1):3-11. (PMID: 12921773)
Nature. 2018 Feb 22;554(7693):544-548. (PMID: 29443960)
Front Immunol. 2021 Dec 23;12:769685. (PMID: 35003085)
Cancers (Basel). 2018 Dec 05;10(12):. (PMID: 30563080)
Eur J Pharmacol. 2020 Jun 15;877:173090. (PMID: 32234529)
Pathol Res Pract. 2023 May;245:154431. (PMID: 37060824)
Mediators Inflamm. 2017;2017:6027305. (PMID: 29234189)
Clin Transl Med. 2021 Dec;11(12):e601. (PMID: 34936229)
Cancer Gene Ther. 2022 Dec;29(12):1988-2000. (PMID: 35915245)
Cancers (Basel). 2020 May 21;12(5):. (PMID: 32455607)
Oncol Lett. 2020 Jun;19(6):3634-3642. (PMID: 32391089)
Int Immunopharmacol. 2021 Jan;90:107146. (PMID: 33189610)
J Cell Physiol. 2019 Jun;234(6):8509-8521. (PMID: 30520029)
Cancer Cell. 2012 Mar 20;21(3):309-22. (PMID: 22439926)
Eur Urol. 2020 Apr;77(4):420-433. (PMID: 31563503)
Clin Cancer Res. 2012 Jun 15;18(12):3377-86. (PMID: 22553347)
Lancet. 2012 Apr 28;379(9826):1591-601. (PMID: 22440947)
Lancet Oncol. 2013 Aug;14(9):863-72. (PMID: 23823157)
Adv Exp Med Biol. 2014;816:183-96. (PMID: 24818724)
Aging (Albany NY). 2020 Nov 18;12(22):23306-23325. (PMID: 33221763)
Clin Chim Acta. 2021 Dec;523:365-373. (PMID: 34687700)
Future Oncol. 2021 Aug;17(23):3061-3076. (PMID: 34156282)
Eur Urol. 2018 Dec;74(6):784-795. (PMID: 30268659)
Nat Rev Cancer. 2013 Nov;13(11):759-71. (PMID: 24154716)
Front Immunol. 2023 Nov 20;14:1275033. (PMID: 38053997)
Nucleic Acids Res. 2016 May 5;44(8):e71. (PMID: 26704973)
Immunity. 2019 Jul 16;51(1):27-41. (PMID: 31315034)
Urol Oncol. 2007 May-Jun;25(3):260-8. (PMID: 17483025)
J Cancer. 2017 Mar 7;8(5):852-860. (PMID: 28382148)
Cancer Med. 2020 Apr;9(8):2774-2790. (PMID: 32096345)
Front Genet. 2021 Nov 08;12:736766. (PMID: 34819945)
J Clin Oncol. 2012 Apr 1;30(10):1107-13. (PMID: 22370319)
Science. 2012 Oct 5;338(6103):120-3. (PMID: 22903521)
Lancet Oncol. 2014 Oct;15(11):e493-503. (PMID: 25281468)
Eur J Cancer. 2000 Jul;36 Suppl 2:7-12. (PMID: 10908842)
PLoS One. 2011 Jan 07;6(1):e16089. (PMID: 21249211)
J Clin Oncol. 2022 Jun 20;40(18):2013-2022. (PMID: 35254888)
معلومات مُعتمدة: 2022A1515012318 Natural Science Foundation of Guangdong Province; 14zxqk08 Sun Yat-sen University Cancer Center Medical Scientist Training Program
المشرفين على المادة: EC 1.14.14.1 (Retinoic Acid 4-Hydroxylase)
تواريخ الأحداث: Date Created: 20240112 Date Completed: 20240115 Latest Revision: 20240116
رمز التحديث: 20240116
مُعرف محوري في PubMed: PMC10786915
DOI: 10.1038/s41598-024-51158-9
PMID: 38216619
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-51158-9